Meeting
2022 ASCO Genitourinary Cancers Symposium
Systematic literature review (SLR) and network meta-analysis (NMA) of first-line therapies (1L) for locally advanced/metastatic urothelial carcinoma (la/mUC).
Authors
Lisa Bloudek
Curta Inc., Seattle, WA
Lisa Bloudek , Zsolt Hepp , Caroline McKay , Christina Louise Derleth , Jennifer Susan LIll , Enrique Lenero , Phoebe Wright , Scott David Ramsey , Sean D. Sullivan , Beth Devine
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Urothelial Carcinoma
Track
Urothelial Carcinoma
Sub Track
Other
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 570)
DOI
10.1200/JCO.2022.40.6_suppl.570
Abstract #
570
Poster Bd #
K11
Abstract Disclosures
Similar Posters
First Author: Matt D. Galsky
Poster
2024 ASCO Genitourinary Cancers Symposium
Avelumab first-line maintenance therapy for locally advanced/metastatic urothelial carcinoma: Results from the real-world US PATRIOT-II study.
First Author: Petros Grivas
Poster
2023 ASCO Genitourinary Cancers Symposium
Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Long-term follow-up from the JAVELIN Bladder 100 trial in subgroups defined by 1L chemotherapy regimen and analysis of overall survival (OS) from start of 1L chemotherapy.
First Author: Srikala S. Sridhar
Poster
2022 ASCO Genitourinary Cancers Symposium
Trial in progress: A phase 2, randomized, open-label study of trilaciclib with first-line, platinum-based chemotherapy and avelumab maintenance in untreated patients with locally advanced or metastatic urothelial carcinoma (PRESERVE 3).
First Author: Guru P. Sonpavde